Amy Krambrink

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211

Roy M. Gulick, Zhaohui Su, Charles Flexner et al. · The Journal of Infectious Diseases · 2007 · 239 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort

K. R. Robertson, Zhaohui Su, David M. Margolis et al. · Neurology · 2010 · 212 citations · Full text

Medicine, Neurology, Neuroscience +13

Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection

Holly Janes, David P. Friedrich, Amy Krambrink et al. · The Journal of Infectious Diseases · 2013 · 76 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Interruption of Antiretroviral Treatment in HIV‐Infected Patients with Preserved Immune Function Is Associated with a Low Rate of Clinical Progression: A Prospective Study by AIDS Clinical Trials Group 5170

Daniel J. Skiest, Zhaohui Su, Diane V. Havlir et al. · The Journal of Infectious Diseases · 2007 · 69 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +11

Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy

Bruce R. Schackman, Heather J. Ribaudo, Amy Krambrink et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2007 · 63 citations

Public Health, Infectious Diseases, Clinical Epidemiology +11